Currently, it does not seem so and so one should think and think again about doing them especially for their high cost.
Published on March 02, 2020
Background
About 25% of pancreatic cancers harbor actionable molecular alterations, defined as molecular alterations for which there is a specific available therapy or drug that is based on evidence of a predictive benefit (note, not proven).
This was a retrospective study
Why should retrospective studies be approached with caution?
Retrospective studies have disadvantages – therefore, their results are not conclusive and reliable enough to make a consented treatment decision.
Retrospective studies are designed to analyze pre-existing data, and are subject to numerous biases as a result:
- Inferior level of evidence compared with prospective studies
- Controls are often recruited by convenience sampling, and are thus not representative of the general population and prone to selection bias
- Prone to recall bias or misclassification bias
- Subject to confounding
- Cannot determine causation, only association
- Some key statistics cannot be measured
- Temporal relationships are often difficult to assess
- Retrospective cohort studies need large sample sizes if outcomes are rare.
About the Study
The researchers sought to retrospectively determine whether patients with pancreatic cancer whose tumors harbored such actionable molecular alterations and who received molecularly matched therapy had a longer median overall survival than similar patients who did not receive molecularly matched therapy.
Results
- 46 patients with actionable molecular alterations who received a matched therapy had median overall survival of 2·58 years as compared to 1·51 years in 143 patients who only received unmatched therapies.
- The 46 patients who received a matched therapy also had 2·58 years overall survival vs 1·32 years in the 488 patients who did not have an actionable molecular alteration.
- However, median overall survival did not differ between the patients who received unmatched therapy and those without an actionable molecular alteration.
Conclusions
- To date, there is no evidence that molecular genetic testing actually contributes to better treatments that extend the life of pancreatic cancer patients.
- The most relevant test for pancreatic cancer today is a BRCA test and can be done at the pathology institutes of the medical centers, until proven otherwise.
- A therapeutic strategy based only on genetic testing in pancreatic cancer patients is merely one and is unproven strategy and therefore other advanced treatment options with cancer treatments and drugs that work in other strategies should be explored.
The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.
Contact us to find out what is the best treatment for YOU
TRIAL•IN Pharma
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039